Abstract
It is aimed to investigate the clinical value of low-molecular-weight heparin in treatment of pulmonary heart disease complicated with respiratory failure. Between January 2018 and April 2019, we included 120 pulmonary heart disease patients complicated with respiratory failure in this study and divided them into two groups using the double-blind, random method, i.e. the control group and the observation group, with 60 patients in each group. After admission, patients in two groups undertook the regular treatment, while those in the observation group additionally took low molecular weight heparin at 5000 U via subcutaneous injection, twice per d. Before and after treatment, arterial blood-gas indicators [partial pressure of carbon dioxide, partial pressure of oxygen and pH value] and the indicators of hemorheology (high blood viscosity, hematocrit and fibrinogen) and clinical efficacy were evaluated for patients in two groups. Prior to the treatment, comparison of the levels of partial pressure of carbon dioxide, partial pressure of oxygen, pH value, high blood viscosity, hematocrit and fibrinogen between two groups showed no significant differences, while after treatment, significant improvement was demonstrated in these indicators in the observation group as compared to those in the control group (p 0.05). In the observation group, patients had an effectiveness rate of 88.33 % (53/60), significantly higher than 63.33 % (38/60) in the control group (p 0.05), while patients in the observation group had shorter hospitalization time [(14.7±0.4) d] than that [(16.9±0.3) d] in the control group (p<0.05). For pulmonary heart disease patients complicated with respiratory failure, medication of low-molecular-weight heparin gained promising efficacy, with significant improvement in the blood performance, ventilation, and heart and lung functions of patients, thereby increasing the survival rate and shortening the hospitalization time of patients. Thus, it is worthy of being promoted in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
